In large clinical trials in patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) significantly prevented the progression of diabetic nephropathy to ESRD [154,155]. This evidence concerns the gene SLC5A2 and diabetic kidney disease.